Navigation Links
LPGA Pro, Jill McGill, Encourages Indoor and Outdoor Allergy Sufferers to Challenge Their Course
Date:2/28/2008

al and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.

The use of XYZAL(R) is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL(R) or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of adult and adolescent patients (12 years of age and older) taking XYZAL(R) 2.5 mg, XYZAL(R) 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs < 1% placebo), somnolence (3% vs < 1% placebo), and epistaxis (2% vs < 1% placebo).

Please visit http://www.XYZAL.com for full prescribing information.

About Allergic Conditions

Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
2. One Year On, ALLERCA Hypoallergenic Cats Bring Sneeze Free Companionship to Allergy and Asthma Sufferers
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
5. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
6. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
7. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
8. MIT researcher addresses biomedical engineering challenges
9. GPhA Annual Meeting Focuses on Industry Opportunities and Challenges for 2008
10. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
11. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: ... and pharmaceutical raw materials,for use in pharmaceutical, nutraceutical ... financial results second quarter 2008 which,ended June 30 ... markets close., Huifeng,s earnings release and related ...
... 4 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarterly royalty payment of approximately $2.1 million ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease. ... quarterly royalty payments on certain,sales of Memantine ...
... announced partnership, Grid Dynamics and GridGain teamed up to develop the ... ... San Francisco, CA (PRWEB) August 4, 2008 -- Following ... up to develop the largest publicly known grid scalability test for ...
Cached Biology Technology:Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 2Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 3
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... The University of Miami,s Rosenstiel School of Marine and ... E.M. Rickaby, Ph.D., as recipient of the 2009 Rosenstiel ... Fellow of Wolfson College, Rickaby works in the Department ... current research on the interaction between marine phytoplankton and ...
... of years, green plants have employed photosynthesis to capture ... A goal of scientists has been to develop an ... produce liquid fuels from carbon dioxide and water. Researchers ... Laboratory (Berkeley Lab) have now taken a critical step ...
... the sea, and are responsible for providing nearly half of ... However, unlike their counterparts on land, the marine plants ... human sight. Consequently, we are still in a very ... phytoplankton biology and ecology. In a new paper published ...
Cached Biology News:Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 2Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 3Turning sunlight into liquid fuels 2Turning sunlight into liquid fuels 3A new view of oceanic phytoplankton 2A new view of oceanic phytoplankton 3
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Biology Products: